Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: A 10-year experience

11Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background. Cytomegalovirus (CMV) remains an important pathogen in transplant patients, and valacyclovir (VACV) prophylaxis 8 g/day has been used in high-risk CMV-seromismatched [D+/R-] renal transplant patients to decrease CMV disease. Neurotoxic adverse effects have limited its use, and the aim of the present study was to retrospectively evaluate low-dose VACV prophylaxis, 3 g/day for 90 days after transplantation, in 102 D+/R- renal transplant patients. Methods. We compared patient and graft survival rates up to 5 years after transplantation with the data from the Collaborative Transplant Study Group (CTS) database. The incidence of CMV disease, rejection and neurotoxic adverse effects was analyzed up to 1 year after transplantation. Results. The patient and graft survival rates up to 5 years were comparable with those derived from the CTS. CMV disease was diagnosed in 25% of the patients and 2% developed tissue-invasive CMV disease. The rejection frequency was 22% and neurotoxic adverse effects were seen in 2% of the patients. Conclusion. sLow-dose VACV prophylaxis (3 g/day) for 90 days post-transplantation results in high patient and graft survival rates and reduces the incidence of CMV disease. Neurotoxic adverse effects are minimal. We believe that low-dose VACV prophylaxis should be considered to form one of the arms in future prospective comparison studies for the prevention of CMV disease in the high-risk D+/R- population of renal transplant patients. © 2012 © The Author 2012. Published by Oxford University Press on behalf of ERA-EDTA.

References Powered by Scopus

Definitions of cytomegalovirus infection and disease in transplant recipients

1083Citations
N/AReaders
Get full text

Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients

774Citations
N/AReaders
Get full text

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation

679Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations

100Citations
N/AReaders
Get full text

Epidemiology, risk factors, and outcomes associated with cytomegalovirus in adult kidney transplant recipients: A systematic literature review of real-world evidence

49Citations
N/AReaders
Get full text

Cytomegalovirus prophylaxis in pediatric kidney transplantation: The Dutch experience

16Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Sund, F., Tufveson, G., Döhler, B., Opelz, G., & Eriksson, B. M. (2013). Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: A 10-year experience. Nephrology Dialysis Transplantation, 28(3), 758–765. https://doi.org/10.1093/ndt/gfs531

Readers over time

‘13‘14‘15‘16‘17‘18‘19‘20‘21‘23‘2501234

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 9

60%

Professor / Associate Prof. 3

20%

Researcher 2

13%

Lecturer / Post doc 1

7%

Readers' Discipline

Tooltip

Medicine and Dentistry 14

82%

Pharmacology, Toxicology and Pharmaceut... 1

6%

Computer Science 1

6%

Nursing and Health Professions 1

6%

Save time finding and organizing research with Mendeley

Sign up for free
0